Article

January 10, 2008

Drug combination shows significant survival advantage in metastatic RCC

The combination of bevacizumab (Avastin) and interferon-alpha (Roferon-A) as first-line treatment in patients with metastatic renal cell carcinoma offers significant improvement in progression-free survival compared with interferon-alpha alone, according to a study published in The Lancet (2007; 370:2103-11).

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos

Sandip Prasad, MD, on the approval of mitomycin intravesical solution for LG-IR-NMIBC

Sandip Prasad, MD, on the approval of mitomycin intravesical solution for LG-IR-NMIBC

Jennifer Robles, MD, discusses the growing interest in HoLEP

Jennifer Robles, MD, discusses the growing interest in HoLEP

Suzanne Merrill, MD, on the rationale for BCG plus PD-1/PD-L1 inhibitors in high-risk NMIBC

Suzanne Merrill, MD, on the rationale for BCG plus PD-1/PD-L1 inhibitors in high-risk NMIBC

Related Content

Related Content

Recent Content

FDA grants priority review to gepotidacin for uncomplicated urogenital gonorrhea

FDA grants priority review to gepotidacin for uncomplicated urogenital gonorrhea

Pearls & Perspectives: Bringing the Magic Back to Medicine, with David Canes, MD

Pearls & Perspectives: Bringing the Magic Back to Medicine, with David Canes, MD

Perioperative EV plus pembrolizumab significantly extends EFS, OS in MIBC

Perioperative EV plus pembrolizumab significantly extends EFS, OS in MIBC

Health Canada approves perioperative durvalumab plus chemo for MIBC

Health Canada approves perioperative durvalumab plus chemo for MIBC

View More Recent Content

Terms and Conditions

Do not sell my Personnal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.